Ranbaxy Laboratories reportedly has filed applications seeking to sell drugs in the US, which will be manufactured at its Gurgaon plant, which is not among those barred by the US Food and Drug Administration (FDA). The company has five manufacturing facilities that are registered with the FDA, including Paonta Sahib, Mohali, Toansa, Gurgaon, and Dewas.
Ranbaxy’s Gurgaon plant has a pilot manufacturing line and the company could it scale it up the facility for commercial use, if it secured product approvals from there.
Ranbaxy’s three formulation manufacturing facilities at Paonta Sahib (Himachal Pradesh), Dewas (Madhya Pradesh) and Mohali (Punjab) have received the FDA’s import alert. Further, US regulator has also barred supply of drugs from Ranbaxy’s active pharmaceutical ingredient manufacturing plant in Toansa (Punjab) to the US.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1837.15 |
| Dr. Reddys Lab | 1271.55 |
| Cipla | 1353.85 |
| Zydus Lifesciences | 1070.90 |
| Lupin | 2351.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: